... and a concluding remark especially relevant to those whom vaccines don't protect against severe illness. These people need effective, affordable antivirals!
"Most predictions about the shape of the post–Covid-19 world have been inaccurate — a reflection of rapid changes in knowledge. But we can now see a picture emerging in which use of effective vaccines will continue to be critical over the long term. Increases in asymptomatic infections and mild illnesses in vaccinated people will nonetheless continue to be possible, as variants continue to emerge. Counts of hospitalizations and deaths may be more important in monitoring the overall impact than numbers of cases, as long as the vaccines continue to be largely effective at preventing severe illness. The possibility of severe illnesses in a small proportion of vaccinated people does emphasize one of the greatest unmet needs we currently face: continued emphasis on better therapeutics and antiviral agents, which will not be affected by molecular changes in the virus as much as vaccines are".
In related news, with my emphasis, "UK researchers investigating a cohort of healthcare workers with a strange pre-existing resistance to SARS-CoV-2 infection have discovered a new antigen target for the next generation of COVID-19 vaccines. The researchers speculate the next wave of vaccines using this antigen could potentially protect against all circulating coronaviruses, including those known to cause the common cold.
:
The T-cells detected in the study were trained to target non-structural proteins that play a role in the early stages of the virus’s life cycle. These proteins are part of the virus’s replication transcription complex, more commonly referred to as replication proteins.
Most interestingly, these particular replication proteins are common to all coronaviruses. So the researchers hypothesize those individuals with strong T-cell responses targeting these proteins may have had recent exposure to a more innocuous common-cold-causing coronavirus."
Very interesting, thanks Neil. If dual action, broad target vaccines come out of this research it will be huge. But I guess there will still be a minority of folk whose immune system won't respond, and will need ready-made antibodies. I have high hopes for the dual action monoclonals from GSK-VIR, currently being trialled in the UK agiletrial.net/first-patien...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Growing numbers of the SARS COV2 H69/V70 variant
Covid Vaccination ✈️🚢🚇🚠🚘
cll and the moderna vaccine
Shingles vaccine for cll patients
Immune Compromised Patients May Get 3rd Vaccination
